Surgery for Arrhythmias — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cardiac arrhythmias — abnormal electrical rhythms of the heart — affect more than 40 million people worldwide and range from benign nuisances to life-threatening emergencies. While most arrhythmias are managed with medications or percutaneous catheter-based procedures, a defined subset of patients with recurrent, symptomatic, drug-refractory arrhythmias are candidates for surgical ablation: procedures that create lines of electrical block within the myocardium (heart muscle) to interrupt the aberrant circuits driving the arrhythmia.

The landmark advance in surgical arrhythmia treatment was the Cox-Maze procedure, developed by Dr. James Cox at Washington University, St. Louis, in 1987. The original Maze III operation used a precise pattern of surgical incisions ('cut and sew') through the atrial myocardium to create a geometrically designed maze of electrical pathways that forces the sinus impulse to conduct in one direction to the atrioventricular (AV) node, eliminating the reentrant circuits responsible for atrial fibrillation (AF) while preserving normal AV conduction. The Cox-Maze III procedure achieved freedom from AF in 90–97% of patients at long-term follow-up and remains the gold-standard reference against which all other AF ablation procedures are benchmarked.

However, the technical complexity and prolonged cardiopulmonary bypass time of the cut-and-sew Maze III led to its replacement in most centres by the Cox-Maze IV procedure, which replicates the identical lesion set using bipolar radiofrequency ablation (Medtronic AtriCure) and cryoablation clamps rather than surgical incisions, substantially reducing operative time and blood loss while maintaining equivalent efficacy.

For patients who are not already undergoing open cardiac surgery, the minimally invasive surgical Maze — the Wolf Mini-Maze (developed by Dr. Randall Wolf) and the thoracoscopic bilateral pulmonary vein isolation — offers surgical ablation through small port incisions without sternotomy or cardiopulmonary bypass, enabling treatment of paroxysmal and persistent AF with lower procedural morbidity.

Surgical arrhythmia procedures address several distinct cardiac rhythm disorders, with atrial fibrillation constituting the overwhelming majority of cases.

Atrial fibrillation (AF) — the primary indication: AF is the most common sustained cardiac arrhythmia, affecting approximately 37 million people globally. It results from chaotic, rapid electrical activity in the atria — predominantly triggered by ectopic foci within the pulmonary veins — leading to irregular ventricular rate, impaired atrial contraction (increasing stroke risk 5-fold), and haemodynamic compromise. Surgical ablation is indicated for:

• Paroxysmal, persistent, or long-standing persistent AF that has failed at least one antiarrhythmic drug and one catheter ablation procedure
• AF in patients undergoing concomitant open cardiac surgery (mitral valve repair/replacement, coronary artery bypass grafting, or aortic valve surgery) — in these patients, concomitant Maze IV adds only 15–20 minutes of clamp time and increases AF freedom rates dramatically at no additional operative mortality
• Lone paroxysmal or persistent AF in highly symptomatic patients who prefer a surgical approach or are poor catheter ablation candidates due to anatomy or prior failure

Other arrhythmias treated surgically:

• Wolff-Parkinson-White (WPW) syndrome: An accessory pathway connecting atria and ventricles allows rapid conduction bypassing the AV node, causing supraventricular tachycardia and, rarely, sudden cardiac death. Catheter ablation is first-line, but surgical pathway division has been performed historically and is occasionally indicated when multiple pathways are present or catheter ablation has failed.
• Atrial flutter: Catheter ablation of the cavo-tricuspid isthmus is the standard first-line treatment. Surgical ablation is considered when flutter co-exists with other conditions requiring surgical correction.
• Ventricular tachycardia (VT): Endocardial resection (surgical Dor procedure) or cryosurgical ablation of VT circuits in post-infarct scar tissue, combined with left ventricular restoration surgery, is performed in selected patients with ischaemic cardiomyopathy and medically refractory VT.

Patient selection for surgical arrhythmia treatment requires cardiological, electrophysiological, and cardiac surgical assessment, ideally within a multidisciplinary AF/arrhythmia team.

Indications for surgical Maze (concomitant with other cardiac surgery):

• Any patient with documented paroxysmal, persistent, or long-standing persistent AF who is undergoing planned open cardiac surgery (mitral valve surgery, CABG, AVR) — the concomitant Maze IV adds minimally to operative risk while substantially improving rhythm outcomes
• American Heart Association / European Society of Cardiology (AHA/ESC) guidelines (2020, 2023 update) give a Class I recommendation for concomitant surgical ablation of AF in patients undergoing cardiac surgery who have symptomatic AF

Indications for stand-alone surgical ablation (Mini-Maze / thoracoscopic):

• Symptomatic AF refractory to at least one antiarrhythmic drug and at least one catheter ablation attempt (failure or contraindication)
• Patients with long-standing persistent AF (>1 year) where catheter ablation success rates are low (30–50%) and surgical success rates are superior
• Patients with large left atria (>5.5 cm) where catheter ablation efficacy is substantially reduced
• Patients unable or unwilling to undergo repeat catheter ablation

Pre-operative workup:

• 12-lead ECG and 24–48-hour Holter monitor to document arrhythmia burden and type
• Transoesophageal echocardiogram (TOE) to exclude left atrial appendage (LAA) thrombus before cardioversion or ablation, and to assess mitral valve and left atrial size
• CT pulmonary venogram or MRI to delineate pulmonary vein anatomy (number, ostial diameter, anomalies — common trunk) before ablation
• Coronary angiography or CT coronary angiography in patients with anginal symptoms or risk factors
• Thyroid function tests, electrolytes, renal function — to exclude correctable triggers of AF
• CHA₂DS₂-VASc score calculation for anticoagulation risk stratification and stroke risk assessment

Surgical ablation for AF encompasses a range of techniques differing in invasiveness, lesion set completeness, and energy source. The choice depends on whether AF surgery is performed concomitantly with other cardiac surgery or as a stand-alone procedure.

Cox-Maze IV (concomitant open-heart approach): The current gold-standard for AF ablation, performed on cardiopulmonary bypass via sternotomy or right mini-thoracotomy alongside the primary cardiac procedure. The lesion set creates transmural lines of ablation that replicate the Cox-Maze III incision pattern:

• Bilateral pulmonary vein isolation (encircling all four pulmonary veins individually or as ipsilateral pairs)
• Roof line connecting the left and right pulmonary vein boxes
• Floor line across the posterior left atrium
• Mitral isthmus line from the left inferior pulmonary vein to the mitral annulus
• Right atrial lesion set (cavo-tricuspid isthmus line, superior vena cava isolation)
• Left atrial appendage excision or ligation (eliminates the most common site of AF-related thrombus formation)

Energy sources: Bipolar radiofrequency clamps (AtriCure, Medtronic Cardioblate) apply energy simultaneously to both surfaces of the atrial wall, producing transmural ablation with high reliability. Cryothermy (-60°C) is used for ablation lines near the posterior left atrium (where proximity to the oesophagus requires slower, more controlled energy delivery) and along the mitral annulus.

Wolf Mini-Maze (stand-alone minimally invasive surgical ablation): Developed by Dr. Randall Wolf at the University of Cincinnati, the Wolf Mini-Maze procedure is performed without cardiopulmonary bypass through bilateral mini-thoracotomies (3–4 port incisions on each side of the chest, each 5–10 mm). Using thoracoscopic guidance, the cardiac surgeon:

1. Isolates all four pulmonary veins using a bipolar radiofrequency clamp (AtriCure) with epicardial approach
2. Creates the box lesion (roof and floor lines across the posterior left atrium)
3. Ganglionated plexi (GP) ablation — targeting autonomic ganglia on the epicardial surface that modulate AF triggers
4. Ligates and excises the left atrial appendage (using an AtriClip epicardial clip or stapler)

Thoracoscopic bilateral pulmonary vein isolation (PVI): A more limited version of the Mini-Maze that isolates only the pulmonary veins (without additional connecting lesion lines); appropriate for paroxysmal AF with predominantly pulmonary vein triggers but less effective for persistent AF.

Convergent procedure (hybrid AF ablation): Combines epicardial surgical ablation (posterior left atrial box via subxiphoid access, by the cardiac surgeon) with endocardial catheter ablation (pulmonary vein isolation + mitral isthmus line, by the electrophysiologist) in a hybrid suite. The combined epicardial-endocardial approach creates fully transmural lesions with higher confirmed success rates in persistent AF than either approach alone.

Surgical ablation for AF provides superior freedom from AF compared to antiarrhythmic drugs and catheter ablation, particularly for persistent and long-standing persistent AF.

Cox-Maze IV outcomes (concomitant with cardiac surgery): Multiple prospective series from experienced centres report freedom from AF without antiarrhythmic drugs of 85–93% at 1 year and 75–85% at 5 years for all AF subtypes. For paroxysmal AF specifically, 5-year AF freedom rates approach 90–95%. These results substantially exceed the 40–60% single-procedure success rates of catheter ablation in similar populations.

Wolf Mini-Maze outcomes (stand-alone): The FAST randomised controlled trial (Boersma et al., 2012) compared the Wolf Mini-Maze to catheter ablation in persistent AF patients who had failed at least one prior ablation. At 12 months, 66% of Mini-Maze patients were free from AF versus 37% of catheter ablation patients (p=0.0022). The LAACS-I trial and multiple registry datasets confirm 60–70% off-drug AF freedom at 1 year for persistent AF with the Mini-Maze approach.

Stroke risk reduction: Left atrial appendage exclusion (ligation or clipping) — performed as part of all surgical Maze procedures — eliminates the most common site of AF-related thrombus formation. The LAAOS III randomised trial demonstrated a significant 33% relative reduction in stroke risk with surgical LAA occlusion in patients undergoing cardiac surgery, regardless of post-operative anticoagulation strategy.

Quality of life: Patients who achieve sustained sinus rhythm after surgical ablation report marked improvements in exercise tolerance, symptom burden, and quality of life metrics (AFEQT, EQ-5D) compared to baseline with AF. Those who can discontinue anticoagulation (based on CHA₂DS₂-VASc risk and confirmed sinus rhythm) achieve an additional significant lifestyle benefit.

The risk profile of surgical arrhythmia treatment depends heavily on whether the procedure is concomitant with other cardiac surgery or performed as a stand-alone minimally invasive operation.

Concomitant Cox-Maze IV (open-heart surgery):

• Mortality: Overall in-hospital mortality reflects primarily the risk of the concomitant procedure (e.g., mitral valve surgery 1–3%, CABG 1–2%); the Maze addition itself contributes negligible additional mortality in experienced centres.
• Pacemaker implantation: Sinus node dysfunction causing symptomatic bradycardia or sinus arrest requiring permanent pacemaker occurs in 5–15% of patients; more common in those with pre-existing sinus node disease, long-standing AF, and older age. Patients should be counselled about this possibility pre-operatively.
• Stroke: Risk is reduced by LAA closure but a small per-procedural stroke risk (1–2%) exists during and immediately after the procedure from air emboli or manipulation of the left atrium.
• Standard open-heart surgery complications: Bleeding, wound infection, pleural effusion, pulmonary complications, prolonged ventilation.

Stand-alone minimally invasive surgical ablation (Wolf Mini-Maze, thoracoscopic):

• Conversion to sternotomy: Required in 1–2% of cases due to haemodynamic instability or bleeding not manageable thoracoscopically.
• Phrenic nerve injury: Transient phrenic nerve palsy (causing diaphragmatic dysfunction) occurs in 2–5% of cases, particularly during left-sided pulmonary vein ablation; most recover fully within 3–6 months.
• Pulmonary vein stenosis: A rare but serious complication if the ablation clamp is placed too distally on the pulmonary veins rather than at the ostium. Rates of <1% are reported with bipolar radiofrequency clamps at the recommended placement level.
• Oesophageal injury / atrio-oesophageal fistula: An extremely rare but potentially fatal complication (<0.1%) from posterior left atrial ablation causing thermal injury to the adjacent oesophagus; prevented by monitoring oesophageal temperature during ablation and limiting energy delivery posteriorly.
• Pacemaker implantation: Required in 3–8% of stand-alone surgical ablation cases.
• Pleural effusion: Small ipsilateral pleural effusions are common in the first weeks after thoracoscopic ablation and usually resolve spontaneously; large symptomatic effusions requiring drainage occur in 5–10% of cases.

Blank period and early recurrence: The first 3 months after surgical ablation are the 'blanking period' during which inflammation-related atrial irritability causes frequent AF/flutter episodes that do not necessarily predict long-term ablation failure. Antiarrhythmic drugs and anticoagulation are continued through this period regardless of rhythm.

Recovery after arrhythmia surgery differs substantially between the open-heart concomitant Maze and the minimally invasive stand-alone approaches.

Cox-Maze IV concomitant with open cardiac surgery: Recovery mirrors that of the primary cardiac procedure (e.g., mitral valve surgery or CABG). Patients are extubated in the ICU within 6–24 hours, transferred to the cardiac ward on Day 1–2, and discharged at Day 5–10. Temporary pacing wires are left in place until Day 3–5. Antiarrhythmic drugs (amiodarone 400 mg daily) are started post-operatively and continued for 3–6 months to suppress atrial inflammation during the healing phase. Oral anticoagulation (warfarin or DOAC) continues for a minimum of 3 months post-operatively; its discontinuation thereafter depends on CHA₂DS₂-VASc score, documented sinus rhythm on monitoring, and LAA closure status.

Wolf Mini-Maze / thoracoscopic ablation: Patients are typically extubated in the operating theatre or immediately post-operatively. ICU stay is 12–24 hours; discharge occurs at Day 2–4. Small chest drains (placed during thoracoscopy) are removed before discharge. Pain from port-site incisions is managed with oral analgesics; most patients need only paracetamol and an NSAID after Day 2. Return to light desk work is possible within 2–3 weeks; physically demanding work requires 4–6 weeks. Patients cannot drive until off narcotic medications (typically 1 week).

Rhythm monitoring and follow-up: Electrocardiographic monitoring during the 3-month blanking period is essential. Most centres provide patients with a continuous cardiac monitor (insertable cardiac monitor/Holter patch) from discharge or implant a long-term subcutaneous cardiac monitor (e.g., Medtronic Reveal LINQ) to provide objective long-term rhythm data. Clinic reviews at 3, 6, and 12 months include ECG, ambulatory monitoring, echocardiogram, and assessment of anticoagulation and antiarrhythmic therapy. Decisions on drug discontinuation are made collaboratively between the electrophysiologist and cardiac surgeon at the 3- and 6-month reviews.

Anticoagulation: Stopping anticoagulation after surgical ablation requires confirmed sustained sinus rhythm on monitoring AND a low CHA₂DS₂-VASc score AND documented LAA closure. Patients with CHA₂DS₂-VASc ≥2 (males) or ≥3 (females) are typically advised to continue anticoagulation indefinitely regardless of apparent sinus rhythm, because brief subclinical AF recurrences may not be captured on standard monitoring.

The cost of surgical arrhythmia treatment reflects the complexity of the procedure, the need for specialised cardiac electrophysiology team involvement, and whether the surgery is performed as a stand-alone procedure or concomitantly with other cardiac surgery.

Concomitant Cox-Maze IV (added to primary cardiac surgery): The incremental cost of adding the Maze IV to an existing cardiac procedure is relatively modest — approximately USD 5,000–15,000 additional in the US, representing the extra operative time and the cost of disposable AtriCure bipolar radiofrequency clamp system (USD 2,000–4,000 per procedure). Total cost of the combined procedure (e.g., mitral valve repair + Maze IV) ranges from USD 60,000–120,000 in the United States.

Stand-alone Wolf Mini-Maze / thoracoscopic ablation (United States): USD 35,000–70,000, reflecting cardiac surgical team fees, specialised thoracoscopic ablation disposables, and 2–4 days of hospitalisation.

Catheter ablation of AF (for comparison): USD 20,000–40,000 in the United States per session; success rates for persistent AF are substantially lower than surgical ablation, so cumulative costs from repeat procedures can approach or exceed surgical ablation costs.

International pricing:

• India: Concomitant Maze IV with cardiac surgery USD 12,000–25,000; stand-alone thoracoscopic ablation USD 8,000–18,000 at leading cardiac centres (AIIMS, Fortis Escorts, Narayana Health, Apollo Hospitals). India has world-class cardiac surgery programmes with international outcomes data and costs 70–80% below US pricing.
• Thailand: USD 18,000–35,000 for surgical ablation at Bumrungrad International, Bangkok Heart Hospital, or Samitivej hospitals
• Turkey: USD 12,000–25,000 at leading Istanbul cardiac surgery centres (Acibadem, Florence Nightingale)
• Germany: EUR 25,000–45,000; German cardiac surgery standards are among the highest in Europe
• Singapore: SGD 40,000–80,000 (USD 30,000–60,000) at private cardiac centres

Key cost drivers: AtriCure bipolar radiofrequency disposables (USD 2,000–4,000 per case), cardiac surgery team fees (surgeon + anaesthesiologist + perfusionist + electrophysiologist), post-operative cardiac monitoring (insertable cardiac monitor: USD 5,000–10,000), and long-term anticoagulation management costs.

Surgical arrhythmia treatment exists within a broader continuum of management options, and patients should understand the complete range of alternatives before choosing a surgical approach.

Rate control medications: Beta-blockers (metoprolol, bisoprolol), rate-limiting calcium channel blockers (diltiazem, verapamil), and digoxin control the ventricular rate during AF without attempting to restore sinus rhythm. Rate control alone does not eliminate stroke risk and does not relieve all AF symptoms, but is appropriate for asymptomatic or mildly symptomatic patients — particularly those over 65 with multiple comorbidities where rhythm control offers no mortality benefit (AFFIRM trial).

Antiarrhythmic drugs (AADs) for rhythm control: Flecainide and propafenone (class IC) are effective for paroxysmal AF in patients without structural heart disease. Sotalol and amiodarone provide rhythm control in patients with structural disease; amiodarone is most effective (60–70% 1-year sinus rhythm maintenance) but has significant long-term toxicity (thyroid, pulmonary, hepatic). Dofetilide is an alternative for persistent AF. AADs are the typical first step before ablation is considered.

Catheter ablation: Pulmonary vein isolation (PVI) via catheter is the primary non-surgical ablation technique, performed by cardiac electrophysiologists. Energy sources include radiofrequency (point-by-point or circular catheter), cryoablation (Arctic Front balloon, achieving circumferential PVI in a single freeze), pulsed field ablation (PFA, a newer non-thermal technique using irreversible electroporation — Farapulse, Medtronic PulseSelect — that spares oesophagus and phrenic nerve). For paroxysmal AF, single-procedure catheter ablation success rates are 65–75% off antiarrhythmic drugs at 1 year; for persistent AF, 40–55%. Catheter ablation has a lower periprocedural risk profile than surgery but requires repeat procedures more frequently. The 2020 ESC AF Guidelines give catheter ablation a Class IA recommendation after failure of at least one AAD, and Class IIA for first-line therapy in paroxysmal AF.

Left atrial appendage occlusion devices: For patients with AF and high stroke risk who cannot tolerate long-term anticoagulation, percutaneous LAA closure with the Watchman FLX (Boston Scientific) or Amulet (Abbott) device is FDA-approved and reduces stroke risk comparable to warfarin. This addresses stroke prevention but does not restore sinus rhythm.

Cardioversion: Direct current electrical cardioversion (DCCV) restores sinus rhythm acutely in 80–90% of AF patients but has a high relapse rate (50–70% return to AF within 1 year without AAD maintenance). Chemical cardioversion with ibutilide, flecainide, or amiodarone is used for haemodynamically stable patients. Cardioversion is a temporising measure, not a curative one.